title: Evaluation of fesoterodine fumarate for the treatment of an overactive bladder.
abstract: BACKGROUND
  Fesoterodine fumarate is an approved drug for overactive bladder. The aim of this study is to review the preclinical and most up to date clinical data on fesoterodine, with a special emphasis on its unique pharmacokinetic features and its implications on safety and tolerability in various patient populations.
  
  
  METHODS
  In this review, the authors extensively reviewed available literature via PubMed search regarding fesoterodine, covering its mechanism of action, pharmacodynamics and pharmacokinetics, clinical efficacy, safety, and tolerability.
  
  
  CONCLUSIONS
  Fesoterodine is an anti-muscarinic agent with a unique pharmacokinetic profile. It is a prodrug that is rapidly metabolized to its active form by nonspecific plasma esterases. Its metabolism is independent of the cytochrome P450 enzyme system. This along with its dual excretion pathways and minimal central nervous system penetration leads to less variability in drug exposure and allowance of administration in those with mild to moderate renal and hepatic insufficiency and in the geriatric population.
authors.affiliation: Vanderbilt University Medical Center, Department of Urology , Room A 1302, Medical Center North, Nashville, TN 37232 , USA +1 615 343 5602 ; +1 615 322 8990 ; Stephen.mock@vanderbilt.edu.
authors.forename: Stephen
authors.initials: S
authors.lastname: Mock
authors.forename: Roger R
authors.initials: RR
authors.lastname: Dmochowski
mesh_terms: D000284:Administration, Oral; D000818:Animals; D001559:Benzhydryl Compounds / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics*; D017326:Clinical Trials, Phase III as Topic; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D006801:Humans; D018727:Muscarinic Antagonists / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics*; D011355:Prodrugs / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics*; D016032:Randomized Controlled Trials as Topic; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*; D064804:Urological Agents / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics*
chemical_list: D001559:Benzhydryl Compounds; D018727:Muscarinic Antagonists; D011355:Prodrugs; D064804:Urological Agents; C526675:fesoterodine